Document:

Exhibit 10.15

 

WRITTEN
CONSENT OF

THE BOARD OF

DIRECTORS OF MCTC

HOLDINGS, INC.

 

The undersigned, being members
of the Board of Directors of MCTC Holdings, a Delaware corporation (the “Corporation”), hereby waive all requirements
as to notice of meeting and hereby consent and agree to the adoption of the resolutions set forth below in lieu of taking such
action at a meeting, pursuant to 141(f) of the Delaware General Corporation Law (“DGCL”) and Article IV, Section (c)
and Section (g) of the Corporation’s Bylaws taking the following actions by unanimous written consent to be effective as
of the 31st day of January 2020.

 

WHEREAS, The Company and its
Board of Directors are taking several actions to further improve the management team of the Company, its Board of Directors, and
its strategic planning and operational capacity.

 

NOW, THEREFORE BE IT RESOLVED:

 

I - The Company, with its approval
and consent from its Board of Directors, enters into an acquisition agreement with Lelantos where MCTC acquires all outstanding
shares and all intellectual property of Lelantos, as outlined in the executed documents titled Acquisition Agreement.

 

II- The Company, with its approval
and consent from its Board of Directors, issues as valuable consideration for the Acquisition Agreement, Seller’s Notes in
the amounts of $225,000, $225,000 and $50,000., totaling $500,000.

 

III - The Company, with its
approval and consent from its Board of Directors enters into Independent Consulting Agreement, dated January 31, 2020, with New
Horizons Laboratory Services, Inc., under the terms outlined in the agreement.

 

IV - The Company, with its approval
and consent from its Board of Directors, issues as valuable consideration for the Independent Consulting Agreement with New Horizons
Laboratory Services, Inc., a Long Team Compensation Note in the amount of $100,000.

 

V - The Company, with its approval
and consent from its Board of Directors, modifies the Directors Agreement with Director Manolos deleting the provision providing
for monthly compensation of $7,500.

 

     

     

    

 

VI - The Company, with its approval
and consent from its Board of Directors, modifies the Directors Agreement with Director Nguyen deleting the provision providing
for monthly compensation of $7,500.

 

VII - The Company, with its
approval and consent from its Board of Directors, reaches a settlement with Director Manolos cancelling $53,767.74 of accumulated
compensation as of January 31, 2020 in exchange for 309,010 common shares of the Company.

 

VIII - The Company, with its
approval and consent from its Board of Directors, reaches a settlement with Director Nguyen cancelling $53,767.74 of accumulated
compensation in exchange for 309,010 common shares of the Company.

 

IX - The Company, with its approval
and consent from its Board of Directors, authorizes the issue of 309,010 common shares of the Company to Director Manolos.

 

X - The Company, with its approval
and consent from its Board of Directors, authorizes the issue of 309,010 common shares of the Company to Director Nguyen.

 

XI – The Company, with
its approval and consent from its Board of Directors, reaches a settlement with Director Hymers cancelling $53,767.74 of accumulated
compensation as of January 31, 2020 in exchange for a convertible note in the Company, under the terms outlined in the note issued
by the Company.

 

FURTHER RESOLVED, That
any and all actions heretofore taken by the officer of the Corporation within the terms of the foregoing resolutions are hereby
ratified, approved and confirmed, and declared to be the valid and binding acts and deeds of the Corporation; and

 

FURTHER RESOLVED, That
the officer(s) of the Corporation be hereby authorized, directed and empowered to do all such other acts and things and to execute
and deliver all such certificates or other documents and to take such other actions as he deems necessary or desirable to carry
out the purposes and intents of the above resolutions.

 

IN WITNESS WHEREOF, the undersigned members
of the Board of Directors have executed this instrument effective as of the date first written above.

 

[Signature Page Follows]

 

     

     

    

  

[Signature Page of the Written Action
of the Board of Directors of MCTC Holdings, Inc.]

 

Effective as of this date: Jan
31, 2019

 

DIRECTORS

 

	/s/ Robert L. Hymers, III	 
	Robert L. Hymers, III	 
	 	 
	/s/ Edward Manolos	 
	Edward Manolos	 
	 	 
	/s/ Dan Nguyen	 
	Dan Nguyen	 
	 	 
	/s/ Arman Tabatabei	 
	Arman TabatabeiExhibit 10.16

 

WRITTEN CONSENT OF

THE BOARD OF

DIRECTORS
OF MCTC

HOLDINGS, INC.

 

The undersigned, being
members of the Board of Directors of MCTC Holdings, a Delaware corporation (the “Corporation”), hereby waive all requirements
as to notice of meeting and hereby consent and agree to the adoption of the resolutions set forth below in lieu of taking such
action at a meeting, pursuant to 141(f) of the Delaware General Corporation Law (“DGCL”) and Article IV, Section (c)
and Section (g) of the Corporation’s Bylaws taking the following actions by unanimous written consent to be effective as
of the June 20, 2019.

 

WHEREAS, the Corporation
has determined that it is in the best interest of the Corporation to retain the services of a consultant to advise the Corporation
in patents and innovations of new products, technologies or formulations in accordance with the company’s guidance.

 

WHEREAS, the Corporation
has determined that it is in the best interest of the Corporation to retain Kirby & Padgett LLC (“Kirby”) as a
consultant and advisory to the Corporation for a term of twelve (12) months, effective June 20, 2019. The Corporation shall compensate
Kirby & Padgett LLC Six Hundred Fifty thousand (650,000) in the Corporation’s restricted common shares in lieu of cash.
The value of share price shall be based on the closing date of June 20, 2019.

 

NOW,
THEREFORE BE IT RESOLVED, FURTHER RESOLVED, that any and all actions heretofore taken by the officer of the Corporation
within the terms of the foregoing resolutions are hereby ratified, approved and confirmed, and declared to be the valid and binding
acts and deeds of the Corporation; and

 

FURTHER RESOLVED, That the
officer(s) of the Corporation be hereby authorized, directed and empowered to do all such other acts and things and to execute
and deliver all such certificates or other documents and to take such other actions as the Corporation deems necessary or desirable
to carry out the purposes and intents of the above resolutions.

 

IN
WITNESS WHEREOF, the undersigned members of the Board of Directors have executed this instrument effective as of the
date first written above.

 

     

     

    

 

[Signature Page Follows]

 

[Signature Page of the Written Action of
the Board of Directors of MCTC Holdings, Inc.]

 

Effective as of this date: Jun 20, 2019

 

DIRECTOR

S

 

	/s/
    Robert L. Hymers, III	 	
	Robert
    L. Hymers, III	 	 
	 	 	 
	/s/
    Edward Manolos	 	
	Edward
    Manolos	 	 
	 	 	 
	/s/
    Dan Nguyen	 	
	Dan
    Nguyen	 	 
	 	 	 
	/s/
    Arman Tabatabaei	 	
	Arman
    Tabatabaei	 	 

 

     

     

    

 

WRITTEN CONSENT OF

THE BOARD OF DIRECTORS

OF MCTC HOLDINGS, INC.

 

The undersigned, being members of the Board
of Directors of MCTC Holdings, a Delaware corporation (the “Corporation”), hereby waive all requirements as to notice
of meeting and hereby consent and agree to the adoption of the resolutions set forth below in lieu of taking such action at a meeting,
pursuant to 141(f) of the Delaware General Corporation Law (“DGCL”) and Article IV, Section (c) and Section (g) of
the Corporation’s Bylaws taking the following actions by unanimous written consent to be effective as of the 31st day of
January 2020.

 

WHEREAS, The Company and its Board of Directors
are taking several actions to further improve the management team of the Company, its Board of Directors, and its strategic planning
and operational capacity.

 

NOW, THEREFORE BE IT RESOLVED:

 

The Company, with its approval and
consent from its Board of Directors, appoints Robert L. Hymers III as Chief Financial Officer.

 

The Company, with its approval and
consent from its Board of Directors, enters into an Executive Employment Agreement with Mr. Hymers.

 

The Company, with its approval and
consent from its Board of Directors, issues Mr. Hymers Seven Hundred Fifty Thousand (750,000) restricted common shares. These shares
fully vest as of the date of this Resolution.

 

The Board of Directors votes unanimously
to appoint Melissa Riddell to the Board of Directors in accordance with Section 3.03 of the Company’s Bylaws, which reads:

 

Section 3.03 Newly Created Directorships
and Vacancies. Any newly created directorships resulting from an increase in the authorized number of directors and any vacancies
occurring in the Board of Directors, shall be filled solely by the affirmative votes of a majority of the remaining members of
the Board of Directors, although less than a quorum, or by a sole remaining director. A director so elected shall be elected to
hold office until the earlier of the expiration of the term of office of the director whom he or she has replaced, a successor
is duly elected and qualified or the earlier of such director’s death, resignation or removal.

 

The Board of Directors unanimously
resolves that Melissa Riddell is appointed as an independent director of the Company.

 

     

     

    

 

The Board of Directors unanimously
resolves the entering into an Independent Director Agreement with Melissa Riddell.

 

FURTHER RESOLVED, That any and all actions
were heretofore taken by the officer of the Corporation within the terms of the foregoing resolutions are hereby ratified, approved
and confirmed, and declared to be the valid and binding acts and deeds of the Corporation; and

 

FURTHER RESOLVED, That the officer(s)
of the Corporation be hereby authorized, directed and empowered to do all such other acts and things and to execute and deliver
all such certificates or other documents and to take such other actions as he deems necessary or desirable to carry out the purposes
and intents of the above resolutions.

 

IN WITNESS WHEREOF, the undersigned
members of the Board of Directors have executed this instrument effective as of the date first written above.

 

[Signature Page Follows]

 

     

     

    

 

[Signature Page of the Written Action of
the Board of Directors of MCTC Holdings, Inc.]

 

Effective
as of this date:Jan 31st, 2019

 

DIRECTORS

 

	/s/
    Robert L. Hymers, III	 	
	Robert
    L. Hymers, III	 	 
	 	 	 
	/s/
    Edward Manolos 	 	
	Edward
    Manolos 	 	 
	 	 	 
	/s/
    Dan Nguyen	 	
	Dan
    Nguyen	 	 
	 	 	 
	/s/
    Arman Tabatabaei	 	
	Arman
    Tabatabaei	 	 

 

     

     

    

 

INDEPENDENT DIRECTOR AGREEMENT

 

This
INDEPENDENT DIRECTOR AGREEMENT (the “Agreement”) is dated this 31st of January 2020 (the “Effective Date”)
by and between MCTC HOLDINGS, INC, a Delaware corporation (the “Company”), and Melissa Riddell, an individual resident
of the State of California (the “Director”).

 

WHEREAS, the Company appointed
the Director effective as of the date hereof (the “Effective Date”) and desires to enter into an agreement with the
Director with respect to such appointment; and

 

WHEREAS, the Director is
willing to accept such appointment and to serve the Company on the terms set forth herein and in accordance with the provisions
of this Agreement.

 

NOW, THEREFORE, in consideration
of the mutual covenants contained herein, the parties hereto agree as follows:

 

1. Position.

 

Subject to the terms and provisions of this
Agreement, the Company shall cause the Independent Director to be appointed, and the Independent Director hereby agrees to serve
the Company in such position upon the terms and conditions hereinafter set forth, provided, however, that the Director’s
continued service on the Board of Directors of the Company (the “Board”) after the initial one-year term on the Board
shall be subject to any necessary approval by the Company’s stockholders.

 

2. Duties.

 

(a) During the Directorship Term (as defined
herein), the Director makes reasonable business efforts to attend all telephonic Board meetings and all quarterly pre-scheduled
Board meetings in person. The Director agrees to serve on appropriate subcommittees as reasonably requested and agreed upon by
the Board and the Director, make herself available to the Company at mutually convenient times and places, attend external meetings
and presentations when agreed on in advance, as appropriate and convenient, and perform such duties, services and responsibilities,
and have the authority commensurate to such position.

 

(b) The Director will use her best efforts
to promote the interests of the Company. The Company recognizes that the Director (i) is or may become a full-time executive employee
of another entity and that her responsibilities to such entity must have priority and (ii) sits or may sit on the board of directors
of other entities, subject to any limitations set forth by the Sarbanes-Oxley Act of 2002 and limitations provided by any exchange
or quotation service on which the Company’s common stock is listed or traded. Notwithstanding the same, the Director will
provide the Company with prior written notice of any future commitments to such entities and use reasonable business efforts to
coordinate her respective commitments so as to fulfill her obligations to the Company and, in any event, will fulfill her legal
obligations as a Director. Other than as set forth above, the Director will not, without the prior notification to the Board, engage
in any other business activity which could materially interfere with the performance of her duties, services and responsibilities
hereunder or which is in violation of the reasonable policies established from time to time by the Company, provided that
the foregoing shall in no way limit her activities on behalf of (i) any current employer and its affiliates or (ii) the board of
directors of any entities on which he currently sits. At such time as the Board receives such notification, the Board may require
the resignation of the Director if it determines that such business activity does in fact materially interfere with the performance
of the Director’s duties, services and responsibilities hereunder.

 

     

     

    

 

3. Compensation.

 

(a) Restricted
Stock. The Director shall receive One Hundred thousand (100,000) shares of the Company’s common stock (the “Compensation
Restricted Stock”). Such shares shall vest in twelve (12) equal amounts over a period of twelve (12) months, the initial
amount vesting as of the Effective Date. Notwithstanding the foregoing, if the Director ceases to be a member of Board at any
time during the vesting period for any reason (such as resignation, withdrawal, death, disability or any other reason), then any
unvested shares shall be irrefutably forfeited. Furthermore, the Director agrees that the shares shall be subject to any “lock-up”
agreement required to be signed by the Company’s officers in connection with any financing. The Director understands common
shares are issued as restricted shares and may be restricted from ordinary sales by way of provisions of law, financial industry
regulatory authorities and/or regulations of the U.S. Securities & Exchange Commission .

 

(b) Independent
Contractor. The Director’s status during the Directorship Term shall be that of an independent contractor and not, for
any purpose, that of an employee or agent with authority to bind the Company in any respect. All payments and other consideration
made or provided to the Director under this Section 3 shall be made or provided without withholding or deduction of any kind, and
the Director shall assume sole responsibility for discharging all tax or other obligations associated therewith.

 

(c) Expense Reimbursements. During the Directorship Term, the Company shall reimburse the Director for all reasonable
out-of-pocket expenses incurred by the Director in attending any in-person meetings, provided that the Director
complies with the generally applicable policies, practices and procedures of the Company for submission of expense reports,
receipts or similar documentation of such expenses. Any reimbursements for allocated expenses (as compared to out-of-pocket
expenses of the Director in excess of $100.00) must be approved in advance by the Company.

 

4. Directorship
Term.

 

The “Directorship Term,” as used
in this Agreement, shall mean the period commencing on the Effective Date and terminating on the earlier of the date of the next
annual stockholders meeting and the earliest of the following to occur: (a) the death of the Director; (b) the termination of the
Director from her membership on the Board by the mutual agreement of the Company and the Director; (c) the removal of the Director
from the Board by the majority stockholders of the Company; and (d) the resignation by the Director from the Board.

 

5. Director’s
Representation and Acknowledgment.

 

The Director represents to the Company that
her execution and performance of this Agreement shall not be in violation of any agreement or obligation (whether or not written)
that he may have with or to any person or entity, including without limitation, any prior or current employer. The Director hereby
acknowledges and agrees that this Agreement (and any other agreement or obligation referred to herein) shall be an obligation solely
of the Company, and the Director shall have no recourse whatsoever against any stockholder of the Company or any of their respective
affiliates with regard to this Agreement.

 

     

     

    

 

6. 
Director Covenants.

 

(a) Unauthorized Disclosure. The
Director agrees and understands that in the Director’s position with the Company, the Director has been and will be
exposed to and receive information relating to the confidential affairs of the Company, including, but not limited to,
technical information, business and marketing plans, strategies, customer information, other information concerning the
Company’s products, promotions, development, financing, expansion plans, business policies and practices, and other
forms of information considered by the Company to be confidential and in the nature of trade secrets. The Director agrees
that during the Directorship Term and thereafter, the Director will keep such information confidential and will not disclose
such information, either directly or indirectly, to any third person or entity without the prior written consent of the
Company; provided, however, that (i) the Director shall have no such obligation to the extent such information
is or becomes publicly known or generally known in the Company’s industry other than as a result of the
Director’s breach of her obligations hereunder and (ii) the Director may, after giving prior notice to the Company to
the extent practicable under the circumstances, disclose such information to the extent required by applicable laws or
governmental regulations or judicial or regulatory process. This confidentiality covenant has no temporal, geographical or
territorial restriction. Upon termination of the Directorship Term, the Director will promptly return to the Company and/or
destroy at the Company’s direction all property, keys, notes, memoranda, writings, lists, files, reports, customer
lists, correspondence, tapes, disks, cards, surveys, maps, logs, machines, technical data, other product or document, and any
summary or compilation of the foregoing, in whatever form, including, without limitation, in electronic form, which has been
produced by, received by or otherwise submitted to the Director in the course or otherwise as a result of the
Director’s position with the Company during or prior to the Directorship Term, provided that the Company shall
retain such materials and make them available to the Director if requested by her in connection with any litigation against
the Director under circumstances in which (i) the Director demonstrates to the reasonable satisfaction of the Company that
the materials are necessary to her defense in the litigation and (ii) the confidentiality of the materials is preserved to
the reasonable satisfaction of the Company.

 

(b) Non-Solicitation. During the Directorship
Term and for a period of three (3) years thereafter, the Director shall not interfere with the Company’s relationship with,
or endeavor to entice away from the Company, any person who, on the date of the termination of the Directorship Term and/or at
any time during the one year period prior to the termination of the Directorship Term, was an employee or customer of the Company
or otherwise had a material business relationship with the Company.

 

(c) Insider Provision. The Director agrees
not to trade in the securities of the Company except for the sale of the Director’s Compensation Restricted Shares.

 

     

     

    

 

(d) Remedies. The Director agrees that
any breach of the terms of this Section 6 would result in irreparable injury and damage to the Company for which the Company would
have no adequate remedy at law; the Director therefore also agrees that in the event of said breach or any threat of breach, the
Company shall be entitled to an immediate injunction and restraining order to prevent such breach and/or threatened breach and/or
continued breach by the Director and/or any and all entities acting for and/or with the Director, without having to prove damages
or paying a bond, in addition to any other remedies to which the Company may be entitled at law or in equity. The terms of this
paragraph shall not prevent the Company from pursuing any other available remedies for any breach or threatened breach hereof,
including, but not limited to, the recovery of damages from the Director. The Director acknowledges that the Company would not
have entered into this Agreement had the Director not agreed to the provisions of this Section 6.

 

(e) The provisions of this Section 6 shall
survive any termination of the Directorship Term, and the existence of any claim or cause of action by the Director against the
Company, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement by the Company of
the covenants and agreements of this Section 6.

 

7. Indemnification.

 

The Company agrees to indemnify the Director
for her activities as a member of the Board to the fullest extent permitted under applicable law.

 

8. 
Non-Waiver of Rights.

 

The failure to enforce at any time the provisions
of this Agreement or to require at any time performance by the other party hereto of any of the provisions hereof shall in no way
be construed to be a waiver of such provisions or to affect either the validity of this Agreement or any part hereof, or the right
of either party hereto to enforce each and every provision in accordance with its terms. No waiver by either party hereto of any
breach by the other party hereto of any provision of this Agreement to be performed by such other party shall be deemed a waiver
of similar or dissimilar provisions at that time or at any prior or subsequent time.

 

9. Notices.

 

Every notice relating to this Agreement shall
be in writing and shall be given by personal delivery or by registered or certified mail, postage prepaid, return receipt requested
the Parties at their known address.

 

10. Binding Effect/Assignment.

 

This Agreement shall inure to the benefit of
and be binding upon the parties hereto and their respective heirs, executors, personal representatives, estates, successors (including,
without limitation, by way of merger) and assigns. Notwithstanding the provisions of the immediately preceding sentence, neither
the Director nor the Company shall assign all or any portion of this Agreement without the prior written consent of the other party.

 

11. Entire Agreement.

 

This Agreement (together with the other agreements
referred to herein) sets forth the entire understanding of the parties hereto with respect to the subject matter hereof and supersedes
all prior agreements, written or oral, between them as to such subject matter.

 

     

     

    

 

12. Severability.

 

If any provision of this Agreement, or any
application thereof to any circumstances, is invalid, in whole or in part, such provision or application shall to that extent be
severable and shall not affect other provisions or applications of this Agreement.

 

13. Governing Law.

 

This Agreement shall be governed by and construed
in accordance with the laws of the State of California, without reference to the principles of conflict of laws. All actions and
proceedings arising out of or relating to this Agreement shall be heard and determined in any court in Los Angeles County, California
and the parties hereto hereby consent to the jurisdiction of such courts in any such action or proceeding; provided, however,
that neither party shall commence any such action or proceeding unless prior thereto the parties have in good faith attempted to
resolve the claim, dispute or cause of action which is the subject of such action or proceeding through mediation by an independent
third party.

 

14. Legal Fees.

 

The parties hereto agree that the non-prevailing
party in any dispute, claim, action or proceeding between the parties hereto arising out of or relating to the terms and conditions
of this Agreement or any provision thereof (a “Dispute”), shall reimburse the prevailing party for reasonable attorney’s
fees and expenses incurred by the prevailing party in connection with such Dispute; provided, however, that the Director
shall only be required to reimburse the Company for its fees and expenses incurred in connection with a Dispute if the Director’s
position in such Dispute was found by the court, arbitrator or other person or entity presiding over such Dispute to be frivolous
or advanced not in good faith.

 

15. Modifications.

 

Neither this Agreement nor any provision hereof
may be modified, altered, amended or waived except by an instrument in writing duly signed by the party to be charged.

 

16. Tense and Headings.

 

Whenever any words used herein are in the singular
form, they shall be construed as though they were also used in the plural form in all cases where they would so apply. The headings
contained herein are solely for the purposes of reference, are not part of this Agreement and shall not in any way affect the meaning
or interpretation of this Agreement.

 

17. Counterparts.

 

This Agreement may be executed in two or more
counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument.

 

     

     

    

 

	MCTC HOLDINGS, INC.:	 
	 	 
	/s/ Arman Tabatabaei	 
	Arman Tabatabaei	 
	 	 
	Chief Executive Officer, Chairman, and Director	 
	 	 
	DIRECTOR:	 
	 	 
	/s/ Melissa Riddell	 
	Melissa Riddell	 

 

     

     

    

 

JOINT
IP OWNERSHIP AND CONSULTING AGREEMENT

 

This Agreement (herein, “Agreement”)
between MCTC Holdings, Inc., which may also be known as Cannabis Global, Inc. (herein, “MCTC”) and Kirby & Padgette,
LLC (herein, “Kirby”) is made effective upon the final date of signing by MCTC and Kirby (herein, collectively known
as the “Parties”) below.

 

1. Recitals

 

A. Whereas, MCTC is a corporation registered in
the State of Delaware,

B. Whereas, Kirby is a
Wyoming registered limited liability company,

C. Whereas, David Riddell
is the legal representative of Kirby,

 

NOW THEREFORE,
All Intellectual Property made, developed, conceived, first reduced to practice, fixed in any tangible medium of expression,
or created independently by Kirby, without any contribution from MCTC of any kind prior to this Agreement shall remain the exclusive
property of Kirby. This includes the current products invented, owned, manufactured and/or marketed by Kirby.

 

NOW THEREFORE,
All Intellectual Property made, developed, conceived, first reduced to practice, fixed in any tangible medium of expression,
or created independently by MCTC, without any contribution from Kirby of any kind prior to this Agreement shall remain the exclusive
property of MCTC.

 

NOW THEREFORE, All Intellectual Property jointly
made, developed, conceived, first reduced to practice, fixed in any tangible medium of expression or created by MCTC and Kirby
during the term of this Agreement (“Joint Intellectual Property”), will be the joint property of and the entire right,
title and interest is hereby assigned jointly to MCTC and Kirby. Each Party shall work with the other Party relative to all business
and monetization of such new Joint Intellectual Property and neither Party shall have any preferred rights over the other.

 

NOW THEREFORE, Associated with this Agreement
will be the requirement for Kirby to provide technology consulting to the MCTC on an as needed basic at the rate of 10 hours per
calendar quarter for a period of one year from the final signing date of this agreement. The consulting shall be performed at the
request of MCTC at times acceptable to the Parties.

 

NOW THEREFORE, the Parties agree to the following:

 

2. Joint
Work. The Parties shall work together to develop at least one new invention. This invention will likely involve to infusion of
cannabidiol and/or other cannabinoids into the edible and dissolvable film develop (the “New Invention”) previously
by Kirby.

 

3. Intention
to Protect the New Invention. The Parties shall work together to file, where possible, at least one U.S. and/or internal patents,
trademark, service mark or other similar intellectual property protection of the New Invention or related technologies (the “Joint
Intellectual Property”)

 

    	1 | Page	JOINT IP AGREEMENT	 

     

    

 

4. Joint
Ownership of the New Invention. The New Invention and the resulting intellectual Property will be owned equally by the Parties.

 

5. Joint
Right to Market New Invention. Either Party shall have the right to market the New Invention with any and all revenues, costs and
profits to be shared on a fifty percent/fifty percent (50%/50%) shares by the Parties. All expenses will be agreed to in advance,
with each Party sharing based on predetermined percentages of such expenses.

 

6. Joint Assignment. Each party hereby
assigns and agrees to assign to the other party, or its designees, an undivided one-half its full right, title and interest in
and to all Joint Intellectual Property. Each party agrees that, during the term of this Agreement and subsequent to the completion
or termination of this Agreement, they will, at the other party’s request and expense, execute any and all applications
for U.S and foreign patents, copyrights or other rights and otherwise provide assistance (including, but not limited to, the execution
and delivery of instruments of further assurance or confirmation) to assign an undivided one-half interest in said Joint Intellectual
Property to the other party and to permit the other party to enforce any patents, copyrights or other rights in and to said subject
intellectual property. All copyrightable works that are created pursuant to performance under this Agreement shall be considered
“works made for hire” as defined by U.S. Copyright Law.

 

7. No
Related Patent Filings. The Parties agree not to file any patent, trademark, or copyright applications relating to Joint Intellectual
Property, without first receiving permission form the other party.

 

8. Full
Disclosure. Each of the parties shall promptly and fully disclose to the other party all Joint Intellectual Property and shall
identify and maintain records of Joint Intellectual Property, and a copy of all such records shall be promptly provided to the
other party. Such records shall be considered Confidential Information and subject to Section [x] of this Agreement.

 

9. Scope
of Joint Development. Each of the parties represents, warrants and covenants that any Joint Intellectual Property will be created
solely by their respective Personnel acting within the scope of their employment, or under a written independent contractor agreement
assigning Intellectual Property rights. With respect to Joint Intellectual Property that qualifies as original works of authorship
under the copyright laws (either U.S. or foreign), if any moral rights (either U.S. or foreign) are created, each party hereby
waives and shall cause its Personnel to waive such rights in the Joint Intellectual Property.

 

10. Responsible
Assistance. Each party agrees to perform all acts that the other party may reasonably request to assist in obtaining the full benefits,
enjoyment, rights, title, and interest in the United States and throughout the world, in the Joint Intellectual Property. Such
acts shall include, without limitation, execution of documents, assistance in the prosecution of patents, copyrights, trademarks,
and trade secrets. The parties shall each bear their own expenses under this Section 9.

 

11. Infringement.
Upon learning of any infringement of Joint Intellectual Property, from any source, the parties shall first determine if they desire
to jointly take action to suppress or eliminate such infringement. If the parties decide to take such action jointly, the parties
agree that they will share equally in the expenses related to such actions, and share equally in any recovery as a result of such
action. In the event that either party decides not to participate in such action, the other party shall have sole discretion to
take whatever action it determines is necessary or appropriate under the circumstances, including without limitation legal action
to suppress or eliminate any such infringement, at the acting party’s expense. The non-acting party agrees to cooperate with
the acting party in such action and the acting party agrees that it will reimburse the non-acting party’s reasonable and
actual expenses incurred in such action. The acting party retains all recovery from such action.

 

    	2 | Page	JOINT IP AGREEMENT	 

     

    

 

12. Compensation
to Kirby for Consulting. Kirby shall be compensated for the consulting services outlined here in at a rate of five Thousand Dollars
($5,000) per month (the “Compensation”) for a period of twelve months, while this Agreement is in place. Compensation
will be in the form of restricted shares of MCTC common stock to be valued on the first of each month beginning on July 1, 2019.
The common shares award will be considered earned as of the date of issuance and will be subject to normal selling restriction
outlined by the Securities & Exchange Commission and/or other industry regulators

 

12. Dispute
Resolution. The parties agree to arbitrate any dispute or controversy regarding whether intellectual property should be considered
Joint Intellectual Property, or any other dispute under the Arbitration Rules of the American Arbitration Association, and any
resulting award or judgment shall be binding and non-appealable and shall be entered in any court of competent jurisdiction to
enforce it.

 

13. Entire Agreement. This
AGREEMENT constitutes the entire AGREEMENT and understanding between the parties and supersedes all prior agreements, representations,
promises and/or covenants, whether written or oral.

 

14. Venue.
This AGREEMENT shall be governed in all respects, whether as to validity, construction, capacity, performance, or otherwise, by
the principal statues of the state of California in the United States of America. Any forbearance by a party to this Agreement
in exercising any right or remedy under this agreement or otherwise afforded by applicable law shall not be a waiver or preclude
the exercise of that or any other right or remedy.

 

15. Assignment. Either
Party may assign its rights under the Agreement at anytime.

 

16. No Other Agreements.
No amendments or additions to this AGREEMENT shall be binding unless in writing and signed by both parties, except as herein otherwise
provided.

 

17. Counter
Parts. This Agreement may be executed simultaneously in any number of counterparts. Each counterpart shall be deemed to be an original,
and all such counterparts shall constitute one and the same instrument. Telecopy signatures shall be deemed valid and binding to
the same extent as the original.

 

(the remaining portion of this page is blank - signature page(s)
follow)

 

    	3 | Page	JOINT IP AGREEMENT	 

     

    

 

Agreed to and signed by my hand on the date outlined below:

 

	/s/ Arman Tabatabaei	 
	Arman Tabatabaei	 
	 	 
	6-14-2019	 
	Date Signed	 
	 	 
	/s/ David Riddell	 
	David Riddell	 
	 	 
	06/14/2019	 
	Date Signed	 

 

(end of document)

 

 

	4 | Page	JOINT IP AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]